The primary outcome assessed changes in Integrated Alzheimer's Disease Rating Scale (iADRS) scores over 76 weeks, revealing a substantial delay in clinical deterioration, especially in individuals with mild to moderate tau accumulation and early‐stage amyloid‐positive AD.9 The gene discussed is MAPT; the disease is Alzheimer disease.